Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JMT601 in Relapsed or Refractory CD20-positive B-cell Non-Hodgkin Lymphoma
NCT06725524Phase 1Recruiting
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Oct 2021
- Primary completion
- Dec 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JMT601 in B-cell non-Hodgkin lymphoma, sponsored by Shanghai Jinmante Biotechnology Co., Ltd. Primary endpoints: Dose-limiting toxicity at 28 days, Maximum Tolerated Dose at 28 days and 1 more. Started Oct 2021; status: recruiting.
02
Drugs
JMT601
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT06725524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06725524.